HTA Information Hub

What is HTA? HTA stands for health technology assessment. It examines evidence about medicines, tests and other healthcare technologies to inform healthcare decisions, including those affecting access to treatment.

Choose your route

What would you like to understand?

You do not need previous HTA experience. Choose the route that is most relevant for you.

New to HTA? Start here

How does a new lupus medicine become available?

Hearing about a new medicine does not always mean you can get it where you live. Before that happens, different people look at different questions.

Can this medicine be sold?

Experts look at studies. They check whether the benefits are greater than the risks.

Allowing the medicine to be sold is called marketing authorisation.

How does it compare with other treatments?

Experts look at how well it works, its side effects and how it compares with care people already receive.

This kind of review is called health technology assessment (HTA).

Will people be able to get it in my country?

Countries make their own decisions about which treatments they provide and pay for.

When a health system pays for a medicine, this is often called reimbursement.

And where do patients come in?

People with lupus can explain what it is like to live with the illness. They can describe fatigue, pain, side effects and what matters in everyday life.

When can they contribute? When a particular treatment is being assessed, there may be set opportunities for patients or patient organisations to share their views. Sometimes this is early on, when the questions for the assessment are being decided; sometimes it is while the evidence is being reviewed. These opportunities are not open all the time, and the ways to take part and the deadlines differ between countries.

Good to know: A medicine can be approved for use without being paid for by every national health system. The steps and organisations involved also vary by country.

The essentials

What is health technology assessment?

HTA, in plain language

Health technology assessment (HTA) is a structured way of evaluating health technologies, such as medicines, diagnostic tests and medical devices. It helps decision-makers consider questions such as which treatments should be offered, who might benefit from them and whether a health system should pay for them.

It considers evidence about how well a technology works and how safe it is. Depending on the setting, an assessment can also examine costs, organisational questions and the wider impact on patients and society.

Different health systems use this evidence in different ways. HTA informs decisions: it does not automatically determine whether a treatment is available to every patient.

Why do patient perspectives matter?

Clinical studies are essential, but they may not capture every aspect of living with lupus. Patients can help explain:

  • Which symptoms and outcomes matter in daily life.
  • The burden of existing treatments and side effects.
  • What patients experience as unmet needs.
  • Variation in needs, circumstances and experiences.
Learn about patient involvement

Three related, but distinct, decision processes

01 · AUTHORISATION

Can a medicine be marketed?

Regulators assess quality, safety and efficacy to decide whether a medicine may receive marketing authorisation. This is different from deciding whether a health system will pay for it.

02 · EUROPEAN FRAMEWORK

What does the comparative clinical evidence show?

Under the EU HTA Regulation, joint clinical assessments are being introduced for specified technologies. They examine relative clinical effectiveness and safety, not national prices or reimbursement.

03 · NATIONAL PROCESSES

What happens in a particular health system?

National authorities remain responsible for decisions on use, pricing and reimbursement. Their methods, roles and opportunities for patient participation differ.

The EU framework has applied since 12 January 2025, with a phased expansion of its scope. Not all lupus medicines are currently subject to an EU joint clinical assessment. Countries outside the EU have their own arrangements. Check the European Commission’s overview ↗

National contexts

Understanding HTA in your country

HTA processes are not identical across Europe. The organisations involved, the steps they follow and the opportunities to take part can differ from country to country.

Find a national HTA starting point

The European Commission lists national organisations participating in European joint HTA work. It is a useful place to identify an authority, although your country may have separate bodies responsible for reimbursement and access decisions.

EU coordination group ↗

For national procedures, use the relevant authority’s own guidance.

Find a lupus organisation in your country

Start with a lupus organisation in your country. National groups can offer local knowledge and help you find the right place to ask questions. Lupus Europe’s member directory links to participating organisations.

Find a national member ↗

Lupus Europe Secretariat: secretariat@lupus-europe.org

Patient participation

What can patients add to HTA?

Clinical studies tell us important things about a treatment. People living with lupus can add another kind of knowledge: what the disease, existing care and possible improvements mean in everyday life. The way this input is requested depends on the assessment and the country.

01 · OUTCOMES

Help identify what matters to patients

An assessment may measure disease activity, flares or organ function. Patients can help explain why fatigue, pain, the ability to study or work, treatment side effects and reducing steroid use also matter.

For example: If a study shows improved disease activity, does it also show whether people can do more in their daily lives?

02 · DIFFERENT NEEDS

Explain why experiences vary

Lupus does not affect everyone in the same way. People may have different organ involvement, disease severity, treatment histories and support needs. These differences can help explain which patient groups an assessment needs to consider.

For example: Does the evidence reflect people with lupus nephritis, or people who have already tried several treatments?

03 · EVERYDAY CARE

Describe the reality of current treatment

Patients can describe the practical demands of living with treatment: multiple medicines, appointments, monitoring, side effects, or difficulties getting care. This helps others understand the existing situation against which a new approach is being considered.

For example: What does taking several medicines, or living with long-term steroid side effects, mean in practice?

04 · WAYS TO PARTICIPATE

Share experience through the appropriate process

Depending on the HTA body, participation might mean an interview, a questionnaire, an invitation to contribute as an individual patient expert, or a written submission from an organisation. Not every process offers all these routes.

A useful starting point: Find the relevant national process and check whether, when and how patient contributions are invited.

Not sure where to begin?

You can find a lupus organisation in your country or read the European Commission’s guidance on patient and carer participation in EU joint HTA work. At EU level, individual patient experts are selected under specific rules, including declarations of interests and confidentiality requirements.

A tool for understanding clinical evidence

PICO: four questions behind a clinical assessment

When someone asks, “Does this treatment work better?”, a useful next question is: better than what, for whom, and in which ways? PICO is a framework used to make that question precise. The letters stand for Population, Intervention, Comparator and Outcomes.

Imagine an assessment of a new treatment for lupus. Before looking at the results, we need to know exactly which patients, which treatment, which existing care and which outcomes are being compared. These four parts help us understand the question the evidence is meant to answer.
P
Population

Who is the assessment about?

All people with lupus, or a particular group, such as people with active systemic lupus erythematosus (SLE), or with lupus nephritis (lupus affecting the kidneys)? Do differences in organ involvement, disease severity or previous treatment matter?

I
Intervention

What is being assessed?

The treatment or other health technology being evaluated. For a medicine, this includes how it is intended to be used and for which patients.

C
Comparator

What is it being compared with?

Existing care, another treatment or an appropriate alternative. In lupus, current care may include combinations of medicines and ongoing corticosteroid treatment.

O
Outcomes

What changes are being measured?

These might include flares, disease activity, organ protection or side effects. Patients may also want to know about fatigue, pain, daily functioning and whether steroid exposure can be reduced.

Why this matters: PICO does not tell us whether a medicine should be used. It helps everyone understand the precise question being assessed and whether the outcomes and patient groups considered reflect what matters in lupus.

Lupus Europe evidence library

What do people living with lupus report?

Lupus Europe provides patient-reported information through large multi-country surveys. The country-level reports help readers explore experiences of living with lupus in particular European countries.

2020 survey

Living with Lupus in 2020

These longer country reports describe respondents’ experiences of symptoms, diagnosis, treatment, work, family life and the practical burden of lupus. They can provide context for discussions about unmet needs and everyday impact.

Country-level survey findings
2024 survey

Swiss Knife Survey 2024

These shorter country reports look at symptoms, the burden of lupus, treatment satisfaction, unmet needs and communication with healthcare teams. They can help identify patient priorities that assessments should understand.

Country-level survey findings

Only countries with published country-level reports are listed.

Available country reports

Select a country to open the available original PDF reports.

An example of careful interpretation

From a survey finding to a useful question

In the Swiss Knife Survey 2024 France country report, 67.3% of the 428 respondents answering the unmet-needs question selected less fatigue as an unmet need.

What outcomes would show whether a treatment makes a meaningful difference to patients’ fatigue and daily functioning?

What this supports: fatigue was a frequently reported unmet need among these survey respondents. What it does not establish: that any particular medicine reduces fatigue, or that the results represent everyone with lupus in France. Read the source factsheet ↗

Using these reports responsibly: country reports describe those who responded to each survey. Sample sizes and denominators vary by country and question; participation may not be representative of all people with lupus. The two surveys asked different questions, so differences between years should not be treated as trends without methodological assessment. Original reports and publications provide the necessary context.

Visit the complete Lupus Europe library
Curated resources

Explore HTA information materials

Explore a small collection of curated information about HTA, patient involvement, training, official guidance and practical tools. Each resource opens the provider’s own website.

Questions and terminology

Common questions, explained

Frequently asked questions

I am completely new to HTA. Where should I start?

Start with the essentials. If you want more detail, the resource library includes introductory materials from the European Commission and EUPATI. You do not need specialist knowledge to begin learning.

Is HTA the same as medicine approval?

No. Regulatory approval concerns whether a medicine can be marketed. HTA examines evidence to inform decisions about how technologies should be used, including national coverage and reimbursement decisions.

Does an EU joint clinical assessment determine reimbursement?

No. EU joint clinical assessment reports analyse comparative clinical evidence. National authorities continue to decide on pricing, reimbursement and use in their health systems.

Can a patient organisation participate in every assessment?

Participation routes and eligibility differ by authority and procedure. In EU joint work, selected individual patients and carers contribute as experts. Some national processes also invite submissions or expert nominations from patient organisations.

Can Lupus Europe surveys demonstrate that a treatment works?

No. They describe patients’ experiences and priorities, which can help identify important questions and unmet needs. Clinical effectiveness requires appropriately designed clinical evidence.

Can a volunteer receive more HTA training through Lupus Europe?

Lupus Europe has developed lupus-specific HTA training for national member organisations and their volunteers. Please contact the Secretariat for information on possible learning opportunities.

Small glossary

HTA

Health technology assessment: structured evaluation to support decisions about health technologies.

HTAR

The EU Health Technology Assessment Regulation.

JCA

Joint clinical assessment: EU-level comparative clinical evidence analysis for technologies in scope.

PICO

Population, Intervention, Comparator, Outcomes: a framework for defining clinical assessment questions.

Reimbursement

A health system’s arrangements for covering or paying for a treatment.

Patient-reported evidence

Information provided by patients about experiences, symptoms, needs and outcomes.

Marketing authorisation

Regulatory permission for a medicine to be marketed. This is not the same as a reimbursement decision.

Comparator

The treatment or care against which another option is compared.

Keep learning

Further develop your HTA knowledge

Start with the information and courses in our curated resource library.

Lupus Europe has also developed HTA training specifically for its national member organisations and their volunteers. Get in touch with us to find out more.

Learning from specialists

EUPATI (the European Patients’ Academy on Therapeutic Innovation) develops education for patients about medicines and HTA. EUCAPA (European Capacity Building for Patients) offers structured HTA courses, including introductory options. Explore their materials to find a suitable starting point.

Course dates, availability and eligibility are controlled by the providers.

Independence and purpose: This page provides information and learning resources.

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

‼️ Webinar announcement‼️

✅ Good patient-physician communication is essential to understanding the full impact of lupus.

Clinical assessments can tell us a lot, but they may not always capture everything that matters in everyday life. So how can healthcare professionals and people living with lupus make sure those different perspectives are brought together during consultations?

🟪 On 15 October, we explored the patient perspective on the communication gap in lupus care.

This time, we turn to the physician perspective.

How can healthcare professionals recognise concerns that clinical measures may not capture, and make sure the patient perspective is meaningfully reflected in consultations?

🗣️ With Jeanette Andersen, Chair of Lupus Europe Board, Prof. Maria Dall’Era and Prof. Ronald van Vollenhoven.

📅 19 November 2026
🕖 19:00 CET (i.e. Paris time)
💻 Online
✅ Free to attend

The discussion will bring together patient and physician perspectives on how communication can support shared understanding and agreed next steps in care.

🔗 Don't miss it and join us for this joint The Lupus Academy – Lupus Europe webinar!!

Register here: us06web.zoom.us/webinar/register/WN_pPQAXvBjSEqt0kyW5KCE7w#/registration
...

‼️ Webinar annou

💜 We've taken part in the EULAR PARE Conference 2026 in Brussels! And what an interesting opportunity to discuss the future of AI in healthcare!

🌍 Bringing together more than 100 delegates and speakers from across Europe and beyond, the conference explored some of the most important questions surrounding artificial intelligence in rheumatology and patient advocacy.

From the opportunities and risks of AI to health inequalities, accessibility and European health policy, the discussions highlighted why patient perspectives must be part of the conversation.

🤩 We were particularly proud to see Jeanette Andersen, Chair of the Lupus Europe Board, sharing our experience with #LupusGPT in her presentation, “AI as a Partner in Care: Empowering the RMD Community with Information”.

💡 Jeanette explained how #LupusGPT was developed with patients and clinicians to offer free, multilingual access to reliable lupus information based on validated sources.

She also introduced #EasyLupus, which provides the same trusted information in simpler language, highlighting why accessibility must be considered when developing AI tools.

But one of the most important messages from her presentation went beyond technology.

💜 Patient organisations have much more to contribute to AI than simply using tools developed by others.

As Jeanette highlighted, patient organisations bring lived experience, knowledge of unmet needs, trusted information and an understanding of the barriers people face when accessing health information.

Technology alone cannot tell us what patients really need or what makes a tool genuinely useful.

Patients and patient organisations should not simply be users of AI. They should help shape its development.

👏 A big thank you to EULAR PARE for bringing together so many different perspectives and creating space for meaningful discussions about the future of healthcare and patient involvement!
...

💜 Weve taken part

🦋 One of the greatest strengths of patient organisations is the support, understanding and sense of community they offer to people living with lupus. 💜

🇧🇬 A great example comes from Организация на пациентите с ревматологични заболявания, who shared their psychological support initiative at the #LupusConvention!

💜 Launched in December 2025, this pilot project provides a safe and supportive space where participants can share their experiences and discuss the challenges of living with lupus, from fatigue and anxiety to relationships and everyday life.

👥 Led by a clinical psychologist, the group currently brings together six women. The project is expected to run until December 2026, while the organisation explores funding opportunities to continue and expand the initiative.

Thank you to our Bulgarian colleagues for sharing their experience, and congratulations on the amazing job you are doing! ❤️

🌍 This is just one example of the valuable work patient organisations are doing across Europe, often responding to needs that go beyond medical care. We'll share more in the coming days!

💜 Are you living with lupus? You don't have to navigate everything alone! Your national lupus organisation may offer information, support, activities and opportunities to connect with others who understand your experiences.

🔗 Find your national lupus organisation and get in touch:
lupus-europe.org/lupus-members/
...

Image attachment
Image attachment

💜 Young people living with lupus are not only the future of patient advocacy. Their voices matter today!

On 23 and 24 October, LUPUS EUROPE was delighted to be represented at the first 𝗘𝗣𝗙 𝗬𝗼𝘂𝘁𝗵 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟲 in Brussels by Ana Rita Vieira, from the LUPUS EUROPE Youth Group, and Lena Koskina, LUPUS EUROPE's Youth Group Coordinator.

🌍 Organised by European Patients' Forum and its EPF Youth Group, the Congress brought together young patient advocates from across Europe to explore the challenges facing young people living with chronic conditions, from economic uncertainty and climate change to the barriers they encounter when trying to influence healthcare decisions.

🌟 One particularly important question ran through the discussions: 𝗵𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗺𝗼𝘃𝗲 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝗶𝗺𝗽𝗹𝘆 𝗴𝗶𝘃𝗶𝗻𝗴 𝘆𝗼𝘂𝗻𝗴 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮 𝘀𝗲𝗮𝘁 𝗮𝘁 𝘁𝗵𝗲 𝘁𝗮𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗲𝘆 𝗵𝗮𝘃𝗲 𝗮 𝗿𝗲𝗮𝗹 𝘀𝗮𝘆 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗯𝗲𝗶𝗻𝗴 𝗺𝗮𝗱𝗲❓

The conversations also highlighted something easily overlooked: 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝘀 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗮𝗻 𝗶𝗻𝘃𝗶𝘁𝗮𝘁𝗶𝗼𝗻. Young people living with chronic conditions are often balancing their health with education, employment and financial pressures. Advocacy opportunities need to recognise those realities, and not be accessible only to those who can afford the time and resources to participate.

🦋 At LUPUS EUROPE, supporting the Youth Group means actively helping create those opportunities, connecting young advocates with others across Europe and ensuring their perspectives can meaningfully contribute to the work we do.

Young people living with lupus are already advocates, bringing their experiences, ideas and knowledge into conversations that matter.

💜 Thank you to European Patients' Forum and its EPF Youth Group for bringing everyone together, and to Rita and Lena for representing LUPUS EUROPE at this important Congress!
...

💜 Young people li